Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction

Glioblastoma is the most frequent aggressive primary brain tumor amongst human adults. Its standard treatment involves chemotherapy, for which the drug temozolomide is a common choice. These are heterogeneous and variable tumors which might benefit from personalized, data-based therapy strategies, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Núñez, Luis Miguel, Romero, Enrique, Julià-Sapé, Margarida, Ledesma-Carbayo, María Jesús, Santos, Andrés, Arús, Carles, Candiota, Ana Paula, Vellido, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661707/
https://www.ncbi.nlm.nih.gov/pubmed/33184423
http://dx.doi.org/10.1038/s41598-020-76686-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661707/
https://www.ncbi.nlm.nih.gov/pubmed/33184423
http://dx.doi.org/10.1038/s41598-020-76686-y

Ejemplares similares